ASH 2022: A Dexamethasone Sparing-Regimen with Daratumumab and Lenalidomide in Frail Patients with Newly-Diagnosed Multiple Myeloma: Efficacy and Safety Analysis of the Phase 3 IFM2017-03 Trial
Springer Healthcare IME Independent, CME Accredited Symposium – The 9th COMy World Congress
Salomon Manier
MagnetisMM-3 Results: Elranatamab in Relapsed Myeloma | Int'l Myeloma Fn
Sequencing multiple myeloma using blood tests - ecancer
Genomic Studies Have Identified Multiple Mechanisms of Genetic Changes in Waldenström Macroglobulinemia
Dr.MHB (@DrMHB1) / Twitter
Next generation sequencing identifies smoldering multiple myeloma patients with a high risk of disease progression - ecancer
IgA kappa/IgA lambda heavy/light chain assessment in the management of patients with IgA myeloma - Boyle - 2014 - Cancer - Wiley Online Library
Immunomodulator Drug-Based Therapy in Myeloma and the Occurrence of Thrombosis
Up-front carfilzomib, lenalidomide, and dexamethasone with transplant for patients with multiple myeloma: the IFM KRd final results - ScienceDirect
Springer Healthcare IME Independent, CME Accredited Symposium – The 9th COMy World Congress
Post-Congress webinars – International Academy for Clinical Hematology (IACH)
Global Epigenetic Regulation of MicroRNAs in Multiple Myeloma | PLOS ONE
Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant | Nature Communications
Team : Factors of persistence of leukemic cells - Canther
ide-cel and neurotoxicity | Int'l Myeloma Foundation
PDF) Epidemiological landscape of young patients with multiple myeloma diagnosed before 40 years of age: the French experience
Global Epigenetic Regulation of MicroRNAs in Multiple Myeloma | PLOS ONE
Knowing and Finding the enemy - Roswell Park Comprehensive Cancer Center
Eileen Mary BOYLE | PostDoc /MD | MD/PhD | NYU Langone Medical Center, New York City | NYUMC | Cancer Institute | Research profile
ASH 2022: Multiple Myeloma Highlights - The ASCO Post
